Table 2.
Participants becoming eligible by LLPv2 alone or by either PLCOm2012 or LLPv2, stratified by baseline LLPv2 score
| Baseline LLPv2 risk strata | |||||||||
| 0.0–0.5 | 0.5–1.0 | 1.0–1.5 | 1.5–2.0 | 2.0–2.1 | 2.1–2.2 | 2.2–2.3 | 2.3–2.4 | 2.4–2.5 | |
| LHC attendees, n | 556 | 1997 | 1224 | 981 | 215 | 203 | 134 | 157 | 148 |
| LHC attendees becoming eligible by LLPv2 | 0 (0%) | 269 (13%) | 200 (16%) | 295 (30%) | 85 (40%) | 99 (49%) | 104 (78%) | 99 (63%) | 114 (77%) |
| Years to eligibility by LLPv2, median (IQR) | – | 8 (4–10) | 8 (3–11) | 9 (4–9) | 8 (5–8) | 7 (5–7) | 4 (3–4) | 11 (4–11) | 5 (3–5) |
| Age at becoming eligible by LLPv2, median (IQR) | – | 65 (60–65) | 65 (62–70) | 65 (60–67) | 65 (65–65) | 65 (65–65) | 60 (60–65) | 70 (65–70) | 65 (65–65) |
| Cancers predicted to arise before reaching eligibility by LLPv2 | – | 2.9 (1.1%) | 3.9 (1.9%) | 7.8 (2.6%) | 2.5 (2.9%) | 2.7 (2.7%) | 1.8 (1.8%) | 3.9 (3.9%) | 2.4 (2.1%) |
| LHC attendees ineligible at baseline by either PLCOm2012 or LLPv2, n | 556 | 1826 | 988 | 646 | 126 | 107 | 72 | 67 | 71 |
| LHC attendees becoming eligible by PLCOm2012 or LLPv2 | 15 (2.7%) | 461 (25%) | 282 (29%) | 232 (36%) | 48 (38%) | 46 (43%) | 51 (71%) | 31 (46%) | 44 (62%) |
| Years to eligibility by PLCOm2012 or LLPv2, median (IQR) | 9 (6–15) | 8 (4–12) | 7 (3–10) | 5 (3–8) | 5 (2–7) | 5 (3–7) | 3 (2–4) | 4 (3–5) | 3 (3–5) |
| Age at becoming eligible by PLCOm2012 or LLPv2, median (IQR) | 69 (64–72) | 65 (62–70) | 68 (65–70) | 66 (61–70) | 66 (64–70) | 65 (63–70) | 64 (60–65) | 65 (62–70) | 65 (64–65) |
| Cancers predicted to arise before reaching eligibility by PLCOm2012 or LLPv2 | 0.1 (0.8%) | 5.7 (1.2%) | 4.8 (1.7%) | 4.5 (1.9%) | 0.9 (1.8%) | 0.9 (2.1%) | 0.8 (1.6%) | 0.7 (2.1%) | 0.8 (1.8%) |
LHC, Lung Health Check; LLPv2, Liverpool Lung Project version 2; PLCOm2012, Prostate, Lung, Colorectal and Ovarian trial’s risk model 2012.